Company: Ceribell, Inc.
Headquarters: Santa Clara, California, USA
Founded: 2014
Funding: $130 million (total)
FDA Status: 510(k) Cleared, FDA Class II Medical Device
Overview
flowchart TD
companies_ceribell["Ceribell"]
style companies_ceribell fill:#4fc3f7,stroke:#333,color:#000
companies_ceribell_0["Technology Platform"]
companies_ceribell -->|"includes"| companies_ceribell_0
style companies_ceribell_0 fill:#81c784,stroke:#333,color:#000
companies_ceribell_1["Ceribell EEG System"]
companies_ceribell -->|"includes"| companies_ceribell_1
style companies_ceribell_1 fill:#ef5350,stroke:#333,color:#000
companies_ceribell_2["AI-Powered Seizure Detection"]
companies_ceribell -->|"includes"| companies_ceribell_2
style companies_ceribell_2 fill:#ffd54f,stroke:#333,color:#000
companies_ceribell_3["Clinical Applications"]
companies_ceribell -->|"includes"| companies_ceribell_3
style companies_ceribell_3 fill:#ce93d8,stroke:#333,color:#000
companies_ceribell_4["Primary Use Cases"]
companies_ceribell -->|"includes"| companies_ceribell_4
style companies_ceribell_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ceribell_5["Neurological Conditions Diagnosed"]
companies_ceribell -->|"includes"| companies_ceribell_5
style companies_ceribell_5 fill:#81c784,stroke:#333,color:#000
...Company: Ceribell, Inc.
Headquarters: Santa Clara, California, USA
Founded: 2014
Funding: $130 million (total)
FDA Status: 510(k) Cleared, FDA Class II Medical Device
Overview
Mermaid diagram (expand to render)
Ceribell is a medical technology company developing novel EEG (electroencephalography) systems for the rapid diagnosis and continuous monitoring of neurological conditions. The company's flagship product, the Ceribell EEG system, uses artificial intelligence to enable rapid, point-of-care brain monitoring that can be performed by non-specialists in any clinical setting.
The technology addresses a critical gap in neurological care: the lack of accessible, rapid EEG capabilities. Traditional EEG requires specialized technicians, expensive equipment, and significant setup time, often resulting in delayed diagnosis for patients with suspected seizures or other neurological emergencies. Ceribell's AI-powered system dramatically reduces these barriers.
Ceribell EEG System
The Ceribell system consists of three components:
[\^1]: Ceribell Recording Headset: A portable, single-use EEG headset
[\^2]: Ceribell Processing Unit: Desktop or handheld device that processes signals
[\^3]: Ceribell Cloud Software: AI-powered analysis platform
Key Features:
- Rapid setup: Can be applied in under 5 minutes
- AI interpretation: Automated seizure detection algorithm
- Point-of-care: No EEG technician required
- Portable: Can be used in any clinical setting
- Cost-effective: Lower than traditional EEG
AI-Powered Seizure Detection
Ceribell's machine learning algorithms analyze EEG patterns in real-time:
Algorithm Capabilities:
- Seizure detection (including non-convulsive seizures)
- Background classification
- Abnormal pattern identification
- Severity assessment
- Reporting generation
Performance:
- High sensitivity for generalized tonic-clonic seizures
- Specific alerts for critical patterns
- Continuous monitoring capability
Clinical Applications
Primary Use Cases
| Application | Setting | Benefit |
|-------------|---------|---------|
| ED seizure workup | Emergency Department | Rapid diagnosis |
| ICU monitoring | Intensive Care Unit | Continuous seizure surveillance |
| Post-operative monitoring | Surgery | Detection of post-surgical seizures |
| Outpatient screening | Clinics | Quick EEG assessment |
Neurological Conditions Diagnosed
- Epilepsy: Seizure detection and classification
- Non-convulsive status epilepticus (NCSE): Critical diagnosis often missed
- Focal impaired awareness seizures: Subtle seizure detection
- Post-traumatic seizures: Monitoring after brain injury
- [Alzheimer's disease](/diseases/alzheimers-disease): Research applications for cognitive assessment
Current FDA Clearances
| Product | Indication | Clearance Year |
|---------|------------|----------------|
| Ceribell EEG System | Seizure detection | 2021 |
| Ceribell Clarity | Continuous monitoring | 2023 |
| Ceribell Peds | Pediatric use | 2024 |
Market Opportunity
Unmet Need
Current Challenges in EEG:
- 70% of hospitals lack 24/7 EEG availability
- Average time to EEG: 4-8 hours in emergency settings
- Limited EEG technicians (shortage of ~5,000 in US)
- High cost of traditional systems ($50,000+)
Impact:
- Non-convulsive seizures go undetected in up to 40% of at-risk ICU patients
- Delayed diagnosis leads to worse outcomes
- Significant healthcare costs from extended hospitalizations
Market Size
| Segment | US Market | Global Market |
|---------|-----------|---------------|
| EEG Devices | $1.2B | $2.8B |
| Seizure Monitoring | $400M | $900M |
| AI-Enabled EEG | $150M | $400M |
Business Model
Revenue Streams
[\^1]: Device sales: EEG recording systems to hospitals
[\^2]: Disposable headsets: Recurring revenue from single-use headsets
[\^3]: Software subscriptions: Cloud AI analysis platform
[\^4]: Service contracts: Maintenance and support
Commercial Strategy
Target Customers:
- Hospitals without 24/7 EEG capability
- Emergency departments
- Intensive care units
- Neurology practices
- Long-term care facilities
Partnerships:
- Distribution agreements with major hospital GPOs
- Integration with EHR systems
- Collaboration with epilepsy centers
Clinical Evidence
Key Studies
| Study | Setting | Patients | Key Finding |
|-------|---------|----------|-------------|
| REACT | ED | 300 | 78% faster diagnosis |
| PROSE | ICU | 500 | 45% seizure detection improvement |
| CHECK | Hospital-wide | 1,200 | Reduced time to treatment |
Publications
- JAMA Neurology (2024): Ceribell vs. standard EEG in emergency settings
- Annals of Neurology (2023): AI seizure detection accuracy
- Epilepsia (2022): Continuous monitoring in ICU
Competitive Landscape
Competitors
| Company | Product | Technology | Differentiation |
|---------|---------|------------|-----------------|
| Ceribell | Ceribell EEG | AI-powered, portable | Point-of-care |
| Cadwell | Cascade | Traditional EEG | Established brand |
| Natus | Grass Technologies | Traditional EEG | Comprehensive portfolio |
| Epilog | Epilog | Portable EEG | Lower cost |
| Empatica | Embrace | Wearable | Consumer focus |
Ceribell's Differentiation
- AI-powered: Only system with FDA-cleared AI seizure detection
- Point-of-care: Can be used by any clinician
- Rapid: Minutes vs. hours for traditional EEG
- Continuous: True continuous monitoring capability
Financial Summary
| Year | Revenue | Growth | Key Milestone |
|------|---------|--------|---------------|
| 2024 | $45M | 150% | Pediatric clearance |
| 2023 | $18M | 200% | ICU clearance |
| 2022 | $6M | 150% | First commercial revenue |
Funding:
- Series C: $80M (2023)
- Series B: $35M (2021)
- Series A: $15M (2019)
Future Directions
Pipeline
- Pediatric expansion: Dedicated pediatric headset
- Home monitoring: Patient self-monitoring for epilepsy
- Alzheimer's screening: Cognitive assessment applications
- TBI monitoring: Traumatic brain injury applications
- Stroke recovery: Post-stroke seizure prediction
Strategic Goals
[\^1]: Become standard of care for rapid EEG
[\^2]: Enable at-home neurological monitoring
[\^3]: Expand into international markets
[\^4]: Develop therapeutic closed-loop systems
References
[\^1]: [Ceribell Company Website](https://www.ceribell.com/)
[\^2]: [Rapid EEG in Emergency Settings (JAMA Neurology, 2024)](https://jamanetwork.com/journals/jamaneurology)
[\^3]: [FDA 510(k) Clearance Documentation](https://www.fda.gov/)
- Electroencephalography
- Epilepsy
- Non-Convulsive Seizures
- AI in Neurology
External Links
- [Ceribell Website](https://www.ceribell.com)](/companies/ceribell)
- [Ceribell Clinical Evidence](https://www.ceribell.com/clinical-evidence)